We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.
Find a trial
At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment. Find a trial that might be suitable for you.
Use the search function below to find a clinical trial that may suit you and your cancer diagnosis
KRYSTAL-12
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Locations
Farrer Park
Diagnosis
Lung cancer
Open for recruitment
View Trial
REGENERON_ R1979-ONC-1625
An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma
Locations
Farrer Park
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
ASPEN 06
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Locations
Farrer Park
Diagnosis
Gastric / gastroesophageal cancer
Open for recruitment
View Trial
KRYSTAL-10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
STELLAR 303
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
Viktoria-1
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
HERTHENA–Lung02
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-Based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy.
Locations
Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
View Trial